Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Commitments And Contingencies (Tables)

12 Months Ended

Dec. 31, 2012



Date of Investment		Investment Amount	Shares Issued		Proceeds Remaining in Restricted Cash as of 12/31/12		Deferred Research and Development Arrangement Balance at 12/31/12
9/21/2009	$	3,500,000	3,102,837	$	-	$	-
1/19/2011		3,950,000	2,334,515		178,301		-
12/7/2012		750,000	2,083,333		-		-
12/27/2012		926,000	-		876,000		876,000
Total	$	9,126,000	7,520,685	$	1,054,301	$	876,000